Therapeutic Effectiveness and Safety of Sintilimab-Dominated Triple Therapy in Unresectable Hepatocellular Carcinoma

Scientists evaluated the effectiveness and safety of sintilimab, a programmed cell death protein-1 blockade, combined with sorafenib and transhepatic arterial chemotherapy and embolization in patients with unresectable hepatocellular carcinoma, compared with sintilimab monotherapy and sintilimab-sorafenib duotherapy.